Cantor Fitzgerald Initiates Coverage On Solid Biosciences with Overweight Rating, Announces Price Target of $5
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has initiated coverage on Solid Biosciences (NASDAQ:SLDB) with an Overweight rating and a price target of $5.
September 22, 2023 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Solid Biosciences has been given an Overweight rating and a price target of $5 by Cantor Fitzgerald.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Solid Biosciences. The price target of $5 suggests potential upside, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100